Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. (hereinafter referred to as Wanbang Pharmaceutical) is a core member enterprise of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as Fosun Pharmaceutical, stock code: 600196-SH, 02196-HK). The company was formerly Xuzhou Biochemical Pharmaceutical Factory established in 1981; it was reorganized into Xuzhou Wanbang Biochemical Pharmaceutical Co., Ltd. in 1998; it was changed to Jiangsu Wanbang Biochemical Pharmaceutical Co., Ltd. in 2001; it joined Fosun Pharma in 2004; it was upgraded to Jiangsu Wanbang in 2017. Biochemical Pharmaceutical Group Co., Ltd.

Wanbang Pharmaceutical has established a domestic research and development and production base for gene-engineering drugs for prokaryotic and eukaryotic cells, and is at the forefront of the research and development of recombinant protein drugs such as recombinant human insulin and analogues, recombinant human erythropoietin and other recombinant protein drugs; it is also at the forefront of small molecule and high-difficulty generic drugs. The industry is at the forefront.

Wanbang Pharmaceutical currently holds and manages more than 20 member enterprises, and has built 7 production bases across the country, covering a total area of ​​nearly 1,000 mu. The company actively promotes the integration of quality system with international standards. At present, the company has more than 10 production lines that have passed the inspection and certification of foreign drug regulatory agencies. One of the sterile injection production lines has passed the on-site inspection of the EU and the US FDA, and one oral solid preparation production line has passed the US FDA. On-site inspection.

The drugs operated by Wanbang Pharmaceutical cover chemical raw materials and their preparations, biochemical drugs and biological products, Chinese patent medicines, etc. The company focuses on the research, development, production and sales of drugs in the fields of hyperglycemia, hypertension, hyperlipidemia, hyperuric acid, and anti-tumor. Animal source insulin, Uliton® (febulista tablets), Yibo (EPO), Wansuping® (glimepressin Tablets), Keyuan® (calcium hydroxybenzenesulfonate capsules), heparin sodium and other products It has a large domestic market share; Keyi® (New Compound Aloe Vera Capsules), Kesheng® (Xihuang Capsules), Xiaoxikang Granules, and Dunye Guanxinning Tablets are exclusive varieties. At present, the company has more than ten products with annual sales exceeding 100 million yuan.

Since its establishment, Wanbang Pharmaceutical has always adhered to honest operation and achieved good results of profits for more than 30 consecutive years and positive growth for more than 30 consecutive years. The company's marketing network is spread all over the country, and has established multiple self-operated marketing departments such as prescription drugs, OTCs, and general products; the functions of market, business and administrative support are complete; patient education and customer service are meticulous; overseas business is developing steadily; Internet business is advancing rapidly; marketing The team has more than 3,000 people.